secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axsome Therapeutics, Inc. (AXSM)
CIK:        0001579428
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0000950170-25-004559
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axsome announces preliminary FY2024 revenue $385.2M; Auvelity $291.4M
---------------------------------------------------------------------

- Total product revenue Q4 $118.3M, full year $385.2M (unaudited preliminary).
- Auvelity net product sales Q4 $92.6M, full year $291.4M.
- Sunosi net product revenue Q4 $25.7M, full year $93.8M.
- CEO cites positive Phase 3 results for AXS-05 (Alzheimer's agitation) and AXS-12 (narcolepsy); regulatory filings planned in 2025.
- Active launch preparations underway for AXS-07 (migraine), if approved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1579428/000095017025004559/0000950170-25-004559-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1579428/000095017025004559/axsm-20250113.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-004559

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer